Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | EBP | Q15125 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9950838 | 0.80 | HCRTR2 (0.47) | CHRM5CHRM1CHRM3HCRTR2EBP | |
| SCHEMBL9950661 | 0.79 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL9950858 | 0.77 | CA12 (0.41) | HCRTR2HCRTR1MAPK1ALDH1A1 | |
| SCHEMBL9951521 | 0.73 | HCRTR2 (0.40) | CHRM5CHRM1CHRM3HCRTR2HTT | |
| SCHEMBL9952216 | 0.71 | HCRTR2 (0.73) | HCRTR2HCRTR1 | |
| SCHEMBL8604705 | 0.68 | CYP19A1 (0.70) | EBPSIGMAR1TMEM97KDM4EATM | |
| SCHEMBL30173445 | 0.68 | CYP19A1 (0.70) | EBPSIGMAR1TMEM97KDM4EATM | |
| SCHEMBL2610422 | 0.68 | MAOB (0.34) | HCRTR2HCRTR1 | |
| SCHEMBL31157848 | 0.66 | CYP19A1 (0.77) | MAPTKDM4EATMALDH1A1ABCB1 | |
| SCHEMBL16641094 | 0.66 | CYP19A1 (0.77) | MAPTKDM4EATMALDH1A1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | CHRM5 557/4885CHRM1 109/4885CHRM3 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.